Николай Васильевич Прасолов
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Николай Васильевич Прасолов has a total of 34 co-authors. Here are the top co-authors by number of shared publications:
- E. M. Shulutko
Russian Medical Academy of Continuous Professional Education, Moscow, Russia
3 shared publications - Elena B. Orel
National Medical Research Center for Hematology
2 shared publications - Надежда Витальевна Доброва
ФГБУ «Национальный медицинский исследовательский центр гематологии» Министерства здравоохранения Российской Федерации; Россия, 125167 Москва, Новый Зыковский проезд, 4
2 shared publications A V Grzhimolovskiĭ
1 shared publicationA Yu Bulanov
1 shared publication- Alla Mikhailovna Kovrigina
National Medical Research Center for Hematology
1 shared publication
Latest Publications
- 19 February 2024
- Published by Media Sphere Publishing Group in Stomatologiya
- Vol. 103 (1) , 48-54
Removal of a dermoid cyst of the floor of the mouth in a patient with severe hemophilia A
The article presents a case of a surgical treatment of removing a dermoid cyst of the floor of the oral cavity in a patient with severe hemophilia A. A detailed analysis was carried out of the surgical operation, postoperative management, coagulation factor replacement therapy and accompanying therapy, as well as the features of anesthesia, which allowed a surgical intervention without any hemorrhagic and infectious complications.
- 19 February 2024
- Published by Media Sphere Publishing Group in Stomatologiya
- Vol. 103 (1) , 48-54
Removal of a dermoid cyst of the floor of the mouth in a patient with severe hemophilia A
The article presents a case of a surgical treatment of removing a dermoid cyst of the floor of the oral cavity in a patient with severe hemophilia A. A detailed analysis was carried out of the surgical operation, postoperative management, coagulation factor replacement therapy and accompanying therapy, as well as the features of anesthesia, which allowed a surgical intervention without any hemorrhagic and infectious complications.
- Open Access
- 25 November 2022
- Published by Russian Association of Coloproctology in Koloproktologia
- Vol. 21 (4) , 130-138
Stoma takedown after Hartmann’s procedure in a patient with hemophilia A complicated with production of inhibitor to FVIII (review and case report)
One of the specific manifestations of hemophilia A is the spontaneous abdominal hematoma mimicking the clinical picture of acute abdominal disease. The appearance of auto-antibodies to FVIII leads to a loss of response to replacement hemostatic therapy and requires an individualized approach as well as highly sensitive laboratory monitoring to reduce the risk of uncontrolled bleeding. The paper presents the case of multi-stage surgical treatment of this complication.
- 25 November 2022
- Published by Russian Association of Coloproctology in Koloproktologia
- Vol. 21 (4) , 130-138
Open AccessStoma takedown after Hartmann’s procedure in a patient with hemophilia A complicated with production of inhibitor to FVIII (review and case report)
One of the specific manifestations of hemophilia A is the spontaneous abdominal hematoma mimicking the clinical picture of acute abdominal disease. The appearance of auto-antibodies to FVIII leads to a loss of response to replacement hemostatic therapy and requires an individualized approach as well as highly sensitive laboratory monitoring to reduce the risk of uncontrolled bleeding. The paper presents the case of multi-stage surgical treatment of this complication.
- Open Access
- 25 October 2021
- Published by National Medical Research Center of Hematology of the Ministry of Health of the Russian Federation in Russian journal of hematology and transfusiology
- Vol. 66 (3) , 362-373-373
Effi cacy of splenectomy in primary immune thrombocytopenia
Introduction. Immune thrombocytopenia (ITP) is an autoimmune disorder characterized by isolated thrombocytopenia. Splenectomy is one the most effective treatment methods for this disorder.Aim — to evaluate the effi cacy and safety of a splenectomy in patients with primary immune thrombocytopenia.Subjects and methods. 111 patients (31 males, 80 females) with primary immune thrombocytopenia who were hospitalized to perform laparoscopic splenectomy were included in a prospective study conducted at the National Research Center for Hematology from 2015 to 2019. Disease duration from onset to splenectomy was from 1 month to 51 years. Response to the splenectomy, complications, and correlation with immediate preoperative platelet count were analyzed.Results. Complete response was achieved in 79 (71.2 %) cases, a partial response was achieved in 11 (9.9 %) cases, and in 21 (18.9 %) cases there was no response. Immediate preoperative platelet count was signifi cantly higher in patients with complete response in comparison with the group with no response, median (95% CI): 47 (35–58) vs 16 (9–20), p < 0.001.Multivariate analysis (logistic regression) was performed. According to this regression, a risk factor for an unfavorable response was detected — males > 60 years of age, p = 0.05; RR (95% CI): 2.0 (0.9–7.1). A predictor of unfavorable response was identifi ed – immediate preoperative platelet count < 23 × 109/l (cutoff point determined in ROC-analysis); p = 0.001, RR (95% CI): 2.5 (1.1–8.6). The probability of complete response was lower with the number of treatment lines prior to splenectomy (weak inverse correlation: r S = −0.30; p = 0.01). The frequency of postoperative complications was 12.6 %. According to our follow-up data, a complete response was preserved in 66/79 (83.5 %) of patients, with a follow-up of 2.7 years.Conclusion. Splenectomy is an effective and safe treatment method for ITP. Factors of unfavorable response were identifi ed: males > 60 years of age and immediate preoperative platelet count < 23 × 109/l. It is safe to perform splenectomy regardless of effectiveness of preoperative splenectomy treatment and platelet count.
- 25 October 2021
- Published by National Medical Research Center of Hematology of the Ministry of Health of the Russian Federation in Russian journal of hematology and transfusiology
- Vol. 66 (3) , 362-373-373
Open AccessEffi cacy of splenectomy in primary immune thrombocytopenia
Introduction. Immune thrombocytopenia (ITP) is an autoimmune disorder characterized by isolated thrombocytopenia. Splenectomy is one the most effective treatment methods for this disorder.Aim — to evaluate the effi cacy and safety of a splenectomy in patients with primary immune thrombocytopenia.Subjects and methods. 111 patients (31 males, 80 females) with primary immune thrombocytopenia who were hospitalized to perform laparoscopic splenectomy were included in a prospective study conducted at the National Research Center for Hematology from 2015 to 2019. Disease duration from onset to splenectomy was from 1 month to 51 years. Response to the splenectomy, complications, and correlation with immediate preoperative platelet count were analyzed.Results. Complete response was achieved in 79 (71.2 %) cases, a partial response was achieved in 11 (9.9 %) cases, and in 21 (18.9 %) cases there was no response. Immediate preoperative platelet count was signifi cantly higher in patients with complete response in comparison with the group with no response, median (95% CI): 47 (35–58) vs 16 (9–20), p < 0.001.Multivariate analysis (logistic regression) was performed. According to this regression, a risk factor for an unfavorable response was detected — males > 60 years of age, p = 0.05; RR (95% CI): 2.0 (0.9–7.1). A predictor of unfavorable response was identifi ed – immediate preoperative platelet count < 23 × 109/l (cutoff point determined in ROC-analysis); p = 0.001, RR (95% CI): 2.5 (1.1–8.6). The probability of complete response was lower with the number of treatment lines prior to splenectomy (weak inverse correlation: r S = −0.30; p = 0.01). The frequency of postoperative complications was 12.6 %. According to our follow-up data, a complete response was preserved in 66/79 (83.5 %) of patients, with a follow-up of 2.7 years.Conclusion. Splenectomy is an effective and safe treatment method for ITP. Factors of unfavorable response were identifi ed: males > 60 years of age and immediate preoperative platelet count < 23 × 109/l. It is safe to perform splenectomy regardless of effectiveness of preoperative splenectomy treatment and platelet count.
- 27 September 2020
- Published by Cifra Ltd - Russian Agency for Digital Standardization (RADS) in Тромбоз, гемостаз и реология
- No. 3,p. 118-122
Приобретенная гипопротромбинемия у пациентки с лимфопролиферативным заболеванием в сочетании с волчаночным антикоагулянтом
Введение: Приобретенная гипопротромбинемия, обусловленная циркуляцией волчаночного антикоагулянта (ВА), ассоциируется с высоким риском развития тяжелого кровотечения. Клинический случай: Описан случай приобретенного дефицита протромбина и фактора IX в сочетании с положительным ВА: у пациентки Н. была диагностирована лимфома из клеток маргинальной зоны, выявлен дефицит фактора II (21%) и фактора IX (27,1%), увеличение активированного частичного тромбопластинового времени, протромбинового времени и международного нормализованного отношения, обнаружены положительные маркеры антифосфолипидного синдрома, по данным тромбоэластографии — выраженная гипокоагуляция. Выполнена абдоминальная спленэктомия. Перед операцией пациентке был введен концентрат протромбинового комплекса (КПК) Уман Комплекс Д. И. в дозе 1500 МЕ. После введения КПК мы не достигли целевого значения активности факторов свертывания: фактор II увеличился до 49%, фактор IX — до 47%. Клинически оперативное вмешательство не сопровождалось геморрагическим синдромом. Заключение: Сочетанный приобретенный дефицит протромбина и фактора IX у пациентки Н. с лимфомой при наличии ВА существенно увеличивал риск развития тяжелого интраоперационного кровотечения. Введение КПК с адекватным мониторингом гемостаза позволило избежать развития осложнений в периоперационном периоде. Background: Acquired hypoprothrombinemia due to lupus anticoagulant presence is associated with a high risk of severe bleeding. Clinical case: The article describes the case of acquired prothrombin and factor IX defi ciency combined with a positive lupus anticoagulant (LA). The patient N. was diagnosed lymphoma from marginal zone cells. She had factor II (21%) and factor IX (27.1%) deficit, increased activated partial thromboplastin time, prothrombin time and international normalized ratio, positive markers of antiphospholipid syndrome, severe hypocoagulation according to thromboelastography. An abdominal splenectomy was performed. Before surgery, prothrombin complex concentrate (PCC) Complex DI Uman in a dose of 1500 IU was administrated. After PCC administration, we did not reach the target value of coagulation factors activity: factor II increased to 49%, factor IX — to 47%. Surgery was not associated with hemorrhagic syndrome. Conclusions: The combined acquired defi ciency of prothrombin and factor IX in patient N. with lymphoma and LA significantly increased the risk of severe intraoperative bleeding. PCC administration with adequate monitoring of hemostasis allowed to avoid the development of complications in perioperative period.
- 27 September 2020
- Published by Cifra Ltd - Russian Agency for Digital Standardization (RADS) in Тромбоз, гемостаз и реология
- No. 3,p. 118-122
Приобретенная гипопротромбинемия у пациентки с лимфопролиферативным заболеванием в сочетании с волчаночным антикоагулянтом
Введение: Приобретенная гипопротромбинемия, обусловленная циркуляцией волчаночного антикоагулянта (ВА), ассоциируется с высоким риском развития тяжелого кровотечения. Клинический случай: Описан случай приобретенного дефицита протромбина и фактора IX в сочетании с положительным ВА: у пациентки Н. была диагностирована лимфома из клеток маргинальной зоны, выявлен дефицит фактора II (21%) и фактора IX (27,1%), увеличение активированного частичного тромбопластинового времени, протромбинового времени и международного нормализованного отношения, обнаружены положительные маркеры антифосфолипидного синдрома, по данным тромбоэластографии — выраженная гипокоагуляция. Выполнена абдоминальная спленэктомия. Перед операцией пациентке был введен концентрат протромбинового комплекса (КПК) Уман Комплекс Д. И. в дозе 1500 МЕ. После введения КПК мы не достигли целевого значения активности факторов свертывания: фактор II увеличился до 49%, фактор IX — до 47%. Клинически оперативное вмешательство не сопровождалось геморрагическим синдромом. Заключение: Сочетанный приобретенный дефицит протромбина и фактора IX у пациентки Н. с лимфомой при наличии ВА существенно увеличивал риск развития тяжелого интраоперационного кровотечения. Введение КПК с адекватным мониторингом гемостаза позволило избежать развития осложнений в периоперационном периоде. Background: Acquired hypoprothrombinemia due to lupus anticoagulant presence is associated with a high risk of severe bleeding. Clinical case: The article describes the case of acquired prothrombin and factor IX defi ciency combined with a positive lupus anticoagulant (LA). The patient N. was diagnosed lymphoma from marginal zone cells. She had factor II (21%) and factor IX (27.1%) deficit, increased activated partial thromboplastin time, prothrombin time and international normalized ratio, positive markers of antiphospholipid syndrome, severe hypocoagulation according to thromboelastography. An abdominal splenectomy was performed. Before surgery, prothrombin complex concentrate (PCC) Complex DI Uman in a dose of 1500 IU was administrated. After PCC administration, we did not reach the target value of coagulation factors activity: factor II increased to 49%, factor IX — to 47%. Surgery was not associated with hemorrhagic syndrome. Conclusions: The combined acquired defi ciency of prothrombin and factor IX in patient N. with lymphoma and LA significantly increased the risk of severe intraoperative bleeding. PCC administration with adequate monitoring of hemostasis allowed to avoid the development of complications in perioperative period.
- 28 November 2019
- Published by Cifra Ltd - Russian Agency for Digital Standardization (RADS) in Тромбоз, гемостаз и реология
- No. 4(80),p. 29-38
Three-factor prothrombin complex concentrate in complex therapy of severe intraoperative bleedings in hematology
Введение. Обеспечение гемостаза при тяжелых кровотечениях остается насущной проблемой во всех областях хирургии. Внедрение в практику концентратов факторов для быстрой коррекции гемостаза с прикроватным мониторингом эффективности проводимой терапии становится все более востребованным. Цель исследования: оценить эффективность концентрата протромбинового комплекса (КПК) Уман Комплекс Д. И. в составе комплексной терапии тяжелых кровотечений у пациентов с заболеваниями системы крови. Материалы и методы. В исследование включено 27 пациентов, которым вводили КПК в комплексной терапии интраоперационных кровотечений. Осуществляли контроль состояния гемостаза до и после введения препарата с помощью стандартных коагулологических тестов, определения концентрации факторов свертывания II, IX, X, антитромбина III (AТIII) и тромбоэластографии (ТЭГ). Показания для введения КПК: тяжелое кровотечение, гипокоагуляция по плазменному звену гемостаза, по данным ТЭГ, дефицит факторов протромбинового комплекса. Результаты. После однократного введения КПК в дозе 18 22 МЕ/кг замедление темпа кровотечения с последующей остановкой достигнуто у 24 (88) пациентов. Получен прирост активности факторов свертывания II, IX, X на 17 19. Не зафиксировано побочных реакций после введения препарата, в том числе тромбоэмболических осложнений. Уровень естественного антикоагулянта AТIII существенно не менялся после введения КПК. Заключение. Введение КПК позволило восполнить дефицит факторов протромбинового комплекса с коррекцией гипокоагуляции и остановкой кровотечения без существенного снижения концентрации AТIII, что свидетельствует об отсутствии избыточной тромбогенности препарата в указанных дозах. Introduction. Supporting of hemostasis under severe bleeding remains urgent problem in all areas of surgery. Use of factors concentrates in practice for rapid correction of hemostasis with bedside monitoring is becoming more popular. Aim: to assess the efficiency of prothrombin complex concentrate (PCC) Uman Complex D. I. for treating of severe bleedings in patients with blood system disorders. Materials and methods. The study included 27 patients who were administered PCC in complex therapy of intraoperative bleeding. Hemostasis control before and after drug administration was performed using standard coagulological tests, determining the concentration of coagulation factors II, IX, X, antithrombin III (AТIII) and thromboelastography (TEG). Indications for PCC administration: severe bleeding, hypocoagulation, according to TEG, prothrombin deficiency. Results. After a single PCC administration at a dose of 18 22 IU/kg, the effect was achieved in 24 (88) patients. Content of coagulation factors II, IX, X increased by 17 19. No adverse events reported after drug administration, including thromboembolic complications. Level of AТIII did not significantly change after PCC administration. Conclusion. PCC administration allowed to refund the factors defi cit of prothrombin complex with correction of hypocoagulation, without significant decrease in AТIII content that indicates the absence of excessive thrombogenicity of PCC in chosen doses.
- 28 November 2019
- Published by Cifra Ltd - Russian Agency for Digital Standardization (RADS) in Тромбоз, гемостаз и реология
- No. 4(80),p. 29-38
Three-factor prothrombin complex concentrate in complex therapy of severe intraoperative bleedings in hematology
Введение. Обеспечение гемостаза при тяжелых кровотечениях остается насущной проблемой во всех областях хирургии. Внедрение в практику концентратов факторов для быстрой коррекции гемостаза с прикроватным мониторингом эффективности проводимой терапии становится все более востребованным. Цель исследования: оценить эффективность концентрата протромбинового комплекса (КПК) Уман Комплекс Д. И. в составе комплексной терапии тяжелых кровотечений у пациентов с заболеваниями системы крови. Материалы и методы. В исследование включено 27 пациентов, которым вводили КПК в комплексной терапии интраоперационных кровотечений. Осуществляли контроль состояния гемостаза до и после введения препарата с помощью стандартных коагулологических тестов, определения концентрации факторов свертывания II, IX, X, антитромбина III (AТIII) и тромбоэластографии (ТЭГ). Показания для введения КПК: тяжелое кровотечение, гипокоагуляция по плазменному звену гемостаза, по данным ТЭГ, дефицит факторов протромбинового комплекса. Результаты. После однократного введения КПК в дозе 18 22 МЕ/кг замедление темпа кровотечения с последующей остановкой достигнуто у 24 (88) пациентов. Получен прирост активности факторов свертывания II, IX, X на 17 19. Не зафиксировано побочных реакций после введения препарата, в том числе тромбоэмболических осложнений. Уровень естественного антикоагулянта AТIII существенно не менялся после введения КПК. Заключение. Введение КПК позволило восполнить дефицит факторов протромбинового комплекса с коррекцией гипокоагуляции и остановкой кровотечения без существенного снижения концентрации AТIII, что свидетельствует об отсутствии избыточной тромбогенности препарата в указанных дозах. Introduction. Supporting of hemostasis under severe bleeding remains urgent problem in all areas of surgery. Use of factors concentrates in practice for rapid correction of hemostasis with bedside monitoring is becoming more popular. Aim: to assess the efficiency of prothrombin complex concentrate (PCC) Uman Complex D. I. for treating of severe bleedings in patients with blood system disorders. Materials and methods. The study included 27 patients who were administered PCC in complex therapy of intraoperative bleeding. Hemostasis control before and after drug administration was performed using standard coagulological tests, determining the concentration of coagulation factors II, IX, X, antithrombin III (AТIII) and thromboelastography (TEG). Indications for PCC administration: severe bleeding, hypocoagulation, according to TEG, prothrombin deficiency. Results. After a single PCC administration at a dose of 18 22 IU/kg, the effect was achieved in 24 (88) patients. Content of coagulation factors II, IX, X increased by 17 19. No adverse events reported after drug administration, including thromboembolic complications. Level of AТIII did not significantly change after PCC administration. Conclusion. PCC administration allowed to refund the factors defi cit of prothrombin complex with correction of hypocoagulation, without significant decrease in AТIII content that indicates the absence of excessive thrombogenicity of PCC in chosen doses.
- 18 December 2018
- Published by Cifra Ltd - Russian Agency for Digital Standardization (RADS) in Тромбоз, гемостаз и реология
- No. 4(76),p. 36-43
Prothrombin complex concentrate in therapy of massive postpartum hemorrhage
Введение. Тяжелые послеродовые кровотечения остаются одной из основных причин материнской смертности. Своевременная диагностика нарушений в системе гемостаза и целенаправленная гемостатическая терапия с включением концентратов факторов свертывания может способствовать уменьшению трансфузионной нагрузки и остановке кровотечения. Цель исследования: оценить эффективность концентрата протромбинового комплекса (КПК) «Протромплекс 600» для лечения тяжелых послеродовых кровотечений. Материалы и методы. В исследование включены 44 женщины, которым вводили КПК в комплексной терапии тяжелых послеродовых кровотечений. Осуществляли контроль состояния гемостаза до и после введения препарата с помощью стандартных коагулологических тестов и тромбоэластографии (ТЭГ). Показания для введения КПК: тяжелое послеродовое кровотечение, гипокоагуляция по плазменному звену гемостаза, по данным ТЭГ, увеличение международного нормализованного отношения ≥ 1,5. Результаты. Замедление темпа кровотечения с последующей остановкой достигнута у 38 (86%) рожениц после однократного введения КПК в дозе 10–25 МЕ/кг. Не зафиксировано каких-либо побочных реакций на введение препарата, в том числе тромбогенных осложнений. Уровень антитромбина III у пациенток после инфузии «Протромплекса» не выходил за рамки референсных значений. Заключение. Хороший терапевтический эффект КПК у данной категории больных подтверждает клиническую целесообразность и патогенетическую обоснованность его введения для быстрой коррекции дефицита основных факторов свертывания. Introduction. Severe postpartum hemorrhage remains one of the main causes of maternal mortality. In-time diagnosis of coagulation disorders and targeted therapy, with incorporation of coagulation’s factor concentrates, can help reduce blood components consumption and stop bleeding. Aim: to assess the eff ectiveness of prothrombin complex concentrate (PCC) «Protromplex 600» for treatment of severe postpartum hemorrhage. Materials and methods. PCC was used in complex therapy of severe postpartum hemorrhage in 44 women. Hemostasis was monitored before and after PCC administration using standard coagulological tests and thromboelastography (TEG). Indications for PCC administration: severe postpartum hemorrhage, hypocoagulation in plasma hemostasis link, hypocoagulation according to TEG, increased international normalized ratio ≥ 1.5. Results. Decreasing of bleeding rate with its subsequent stopping was achieved in 38 (86%) post-delivery women after single PCC administration at dose 10–25 IU/kg. No adverse reactions to PCC administration, including thrombogenic complications were fi xed. After «Protromplex 600» infusion antithrombin III level was within the reference values. Conclusion. A good therapeutic effect of CCP in this category of patients confirms the clinical advisability and pathogenetic validity of its administration for the rapid correction major coagulation factors deficiency.
- 18 December 2018
- Published by Cifra Ltd - Russian Agency for Digital Standardization (RADS) in Тромбоз, гемостаз и реология
- No. 4(76),p. 36-43
Prothrombin complex concentrate in therapy of massive postpartum hemorrhage
Введение. Тяжелые послеродовые кровотечения остаются одной из основных причин материнской смертности. Своевременная диагностика нарушений в системе гемостаза и целенаправленная гемостатическая терапия с включением концентратов факторов свертывания может способствовать уменьшению трансфузионной нагрузки и остановке кровотечения. Цель исследования: оценить эффективность концентрата протромбинового комплекса (КПК) «Протромплекс 600» для лечения тяжелых послеродовых кровотечений. Материалы и методы. В исследование включены 44 женщины, которым вводили КПК в комплексной терапии тяжелых послеродовых кровотечений. Осуществляли контроль состояния гемостаза до и после введения препарата с помощью стандартных коагулологических тестов и тромбоэластографии (ТЭГ). Показания для введения КПК: тяжелое послеродовое кровотечение, гипокоагуляция по плазменному звену гемостаза, по данным ТЭГ, увеличение международного нормализованного отношения ≥ 1,5. Результаты. Замедление темпа кровотечения с последующей остановкой достигнута у 38 (86%) рожениц после однократного введения КПК в дозе 10–25 МЕ/кг. Не зафиксировано каких-либо побочных реакций на введение препарата, в том числе тромбогенных осложнений. Уровень антитромбина III у пациенток после инфузии «Протромплекса» не выходил за рамки референсных значений. Заключение. Хороший терапевтический эффект КПК у данной категории больных подтверждает клиническую целесообразность и патогенетическую обоснованность его введения для быстрой коррекции дефицита основных факторов свертывания. Introduction. Severe postpartum hemorrhage remains one of the main causes of maternal mortality. In-time diagnosis of coagulation disorders and targeted therapy, with incorporation of coagulation’s factor concentrates, can help reduce blood components consumption and stop bleeding. Aim: to assess the eff ectiveness of prothrombin complex concentrate (PCC) «Protromplex 600» for treatment of severe postpartum hemorrhage. Materials and methods. PCC was used in complex therapy of severe postpartum hemorrhage in 44 women. Hemostasis was monitored before and after PCC administration using standard coagulological tests and thromboelastography (TEG). Indications for PCC administration: severe postpartum hemorrhage, hypocoagulation in plasma hemostasis link, hypocoagulation according to TEG, increased international normalized ratio ≥ 1.5. Results. Decreasing of bleeding rate with its subsequent stopping was achieved in 38 (86%) post-delivery women after single PCC administration at dose 10–25 IU/kg. No adverse reactions to PCC administration, including thrombogenic complications were fi xed. After «Protromplex 600» infusion antithrombin III level was within the reference values. Conclusion. A good therapeutic effect of CCP in this category of patients confirms the clinical advisability and pathogenetic validity of its administration for the rapid correction major coagulation factors deficiency.
- 8 July 2015
- Vol. 60 (2) , 72-6
[EMERGENCY TREATMENT OF BLEEDING IN PATIENTS TAKING WARFARIN].
Anticoagulant therapy with vitamin K antagonists (AVK) is an effective treatment and prevention of thrombosis. One of the major disadvantages of the AVK is a risk for serious bleeding. Prothrombin complex concentrates (PCC), fresh frozen plasma (FFP) and vitamin K1 are available for control of these situations. The experience of special team ofthe Scientific Center for Hematology was the basis for presented retrospective study. Three regimens of warfarin-related bleeding were compared: PCC+ VK for several bleeding, FFP+ VK for different clinical situations and VKfor light bleeding. PCC showed himself as effective and safe hemostatic agent. Transfusions of FFP were sometimes not effective, sometimes led to TACO. Supplementation of vitamin K1 for patients of I and II groups provided more stable control of hemostasis. In III group VK vas effective to stop bleeding. Two impotent sings for conclusion: necessary of laboratory monitoring, TEG first of all; individual balance of hemostasis base of bleeding or thrombotic risks.
- 8 July 2015
- Vol. 60 (2) , 72-6
[EMERGENCY TREATMENT OF BLEEDING IN PATIENTS TAKING WARFARIN].
Anticoagulant therapy with vitamin K antagonists (AVK) is an effective treatment and prevention of thrombosis. One of the major disadvantages of the AVK is a risk for serious bleeding. Prothrombin complex concentrates (PCC), fresh frozen plasma (FFP) and vitamin K1 are available for control of these situations. The experience of special team ofthe Scientific Center for Hematology was the basis for presented retrospective study. Three regimens of warfarin-related bleeding were compared: PCC+ VK for several bleeding, FFP+ VK for different clinical situations and VKfor light bleeding. PCC showed himself as effective and safe hemostatic agent. Transfusions of FFP were sometimes not effective, sometimes led to TACO. Supplementation of vitamin K1 for patients of I and II groups provided more stable control of hemostasis. In III group VK vas effective to stop bleeding. Two impotent sings for conclusion: necessary of laboratory monitoring, TEG first of all; individual balance of hemostasis base of bleeding or thrombotic risks.
- 1 January 2013
- No. 10,p. 56-9
[The surgical treatment of the late recurrence of the colon cancer].